Expression and mechanism of apoptosis-inducing factor 2 gene in breast cancer

doi:10.3969/j.issn.1006-7795.2023.02.011

Abstract

Abstract: Objective To analyze the expression and mechanism of apoptosis-inducing factor 2 (AIFM2) in breast cancer tissue using bioinformatics methods. Methods The research information of AIFM2 in GEPIA, Kaplan-Meier Plotter, and UALCAN databases were searched, and the expression of this gene in breast cancer was analyzed. The Kaplan-Meier method was used to analyze the relationship between AIFM2 expression and breast cancer patients' survival and clinicopathological factors. Additionally, the LinkedOmic database was used to screen genes co-expressed with AIFM2, and the target genes were subjected to Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis, and the tumor immune estimate resource (TIMER) database was used to explore the correlation between AIFM2 expression and infiltration of immune cells into tumor tissues. Results GEPIA database analysis showed that the expression of AIFM2 in breast cancer was significantly lower than that in normal adjacent tissue (P<0.05). Metastasis-free survival was substantially higher in all patients than in the low-expression group (P<0.05); UALCAN database analysis showed that the expression levels of AIFM2 in breast cancer were different in different races, molecular types, and tissue types (P<0.05). There was no difference in expression levels among age, sex, stage, TP53 mutation, menopausal status and lymph node metastasis (P>0.05). GO and KEGG enrichment analysis of AIFM2 co-expressed genes in the LinkedOmic database revealed that the expression level of AIFM2 in breast cancer was positively correlated with the infiltration of CD4^＋T cells, neutrophils, and dendritic cells (P<0.05). Low levels of infiltrating CD4^＋T cells, CD8^＋T cells, neutrophils, and dendritic cells in breast cancer were significantly associated with poorer survival (P<0.05). ConclusionThe expression of AIFM2 in breast cancer is related to the infiltration of immune cells into tumor tissues. Hence, AIFM2 can be considered a biomarker of the immune cell infiltration, metastasis, and prognosis in breast cancer.

Key words: breast cancer, ferroptosis, apoptosis-inducing factor 2 (AIFM2), immune infiltration, bioinformatics

CLC Number:

R737.9

Yang Yifan, Wang Yamei. Expression and mechanism of apoptosis-inducing factor 2 gene in breast cancer[J]. Journal of Capital Medical University, 2023, 44(2): 248-257.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2023.02.011

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2023/V44/I2/248

References

［1］Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin, 2018, 68(6):394－424．
［2］Sung H, Ferlay J, Siegel R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin, 2021, 71(3):209－249.
［3］Chen X, Kang R, Kroemer G, et al. Broadening horizons: the role of ferroptosis in cancer［J］. Nat Rev Clin Oncol, 2021,18(5):280－296.
［4］Shi L, Liu Y, Li M, et al. Emerging roles of ferroptosis in the tumor immune landscape: from danger signals to anti-tumor immunity［J］. FEBS J, 2022, 289(13):3655－3665.
［5］Lei G, Zhuang L, Gan B. Targeting ferroptosis as a vulnerability in cancer［J］. Nat Rev Cancer, 2022, 22(7):381－396.
［6］Mou Y, Wang J, Wu J, et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer［J］. J Hematol Oncol, 2019, 12(1):34.
［7］Fujihara K M, Zhang B Z, Clemons N J. Opportunities for ferroptosis in cancer therapy［J］. Antioxidants (Basel), 2021, 10(6):986..
［8］Lee, N, Carlisle, A E, Peppers, A, et al. xCT-driven expression of GPX4 determines sensitivity of breast cancer cells to ferroptosis inducers［J］. Antioxidants (Basel), 2021, 10(2):317.
［9］Wen Y, Chen H, Zhang L, et al. Glycyrrhetinic acid induces oxidative/nitrative stress and drives ferroptosis through activating NADPH oxidases and iNOS, and depriving glutathione in triple-negative breast cancer cells［J］. Free Radic Biol Med, 2021, 173:41－51.
［10］Sui S, Xu S, Pang D. Emerging role of ferroptosis in breast cancer: new dawn for overcoming tumor progression［J］. Pharmacol Ther, 2022, 232:107992.
［11］Bersuker K, Hendricks J M, Li Z, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis［J］. Nature, 2019, 575(7784):688－692.
［12］Doll S, Freitas F P, Shah R, et al. FSP1 is a glutathione-independent ferroptosis suppressor［J］. Nature, 2019, 575(7784):693－698.
［13］Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses［J］. Nucleic Acids Res, 2017, 45(W1):W98－W102.
［14］Chandrashekar D S, Bashel B, Balasubramanya S A H, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses［J］. Neoplasia, 2017, 19(8):649－658.
［15］Vasaikar S, Straub P, Wang J, et al. LinkedOmics: analyzing multi-omics data within and across 32 cancer types［J］. Nucleic Acids Res, 2018, 46(D1):D956－D963.
［16］Li T, Fan J, Wang B, et al. TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells［J］. Cancer Res, 2017, 77(21):e108–e110.
［17］Wang, W, Green M, Choi J E, et al. CD8+T cells regulate tumour ferroptosis during cancer immunotherapy［J］. Nature, 2019, 569(7755):270－274.
［18］Kim D H, Kim W D, Kim S K, et al. TGF-β1-mediated repression of SLC7A11 drives vulnerability to GPX4 inhibition in hepatocellular carcinoma cells［J］. Cell Death Dis, 2020, 11(5):406.
［19］Dai E, Han L, Liu J, et al. Ferroptotic damage promotes pancreatic tumorigenesis through a TMEM173/STING-dependent DNA sensor pathway［J］. Nat Commun, 2020, 11(1):6339.
［20］Sun L, Linghu D, Hung M. Ferroptosis：a promising target for cancer immunotherapy［J］. Am J Cancer Res,2021, 11(12):5856–5863.
［21］Lei G, Mao C, Yan Y, et al. Ferroptosis, radiotherapy, and combination therapeutic strategies［J］. Protein Cell, 2021, 12(11):836－857.
［22］Hadian K. Ferroptosis suppressor protein 1 (FSP1) and coenzyme Q10 cooperatively suppress ferroptosis［J］. Biochemistry, 2020, 59(5):637－638.
［23］Venkatesh D, OBrien N A, Zandkarimi F, et al. MDM2 and MDMX promote ferroptosis by PPARα-mediated lipid remodeling［J］. Genes Dev, 2020, 34(7－8):526－543.

[1]	Zhao Yue, Ruan Xiangyan, Cheng Jiaojiao, Gu Muqing, Xu Xin, Wang Yuejiao. Breast cancer pathological diagnosis reveals correlation between progesterone receptor membrane component 1 and clinicopathological parameters [J]. Journal of Capital Medical University, 2022, 43(3): 350-356.
[2]	Wei Changsheng, Luo Chengyu, Zhang Shuqi. Application of periareolar incision combined with mastoscopic axillary lymph node dissection in breast conserving surgery for early breast cancer [J]. Journal of Capital Medical University, 2021, 42(6): 1014-1020.
[3]	. [J]. Journal of Capital Medical University, 2021, 42(4): 672-677.
[4]	Yang Yang, Kang Hua, Zhao Jing, Ling Yuwei, Zhao Ye, Wang Yajun, Rong Dongdong. Retrospective analysis of preoperative breast MRI of breast cancer patients with breast conserving surgery [J]. Journal of Capital Medical University, 2020, 41(6): 943-953.
[5]	Bai Xiangdong, Hao Yating, Zhang Xinxue, He Qiang. Clinical efficacy of lineal polypeptide injection combined with chemotherapy in triple-negative breast cancer patients [J]. Journal of Capital Medical University, 2019, 40(6): 911-915.
[6]	Wang Yuejiao, Ruan Xiangyan, Gu Muqing, Cai Guiju, Li Xue, Zhang Lingyan, Alfred O. Mueck. Tamoxifen treated breast cancer xenograft in nude mice and uterine pathological changes [J]. Journal of Capital Medical University, 2019, 40(4): 539-543.
[7]	Chen Nina, Fan Yichang, Shang Kun, Yang Jing, Cao Bangwei. Serum lipid and apolipoprotein levels were associated to the Ki-67 and molecular classification of breast cancer [J]. Journal of Capital Medical University, 2019, 40(2): 191-194.
[8]	Xu Quan, Liu Yujie, Pan Yu, Zheng Xiuyuan, Liu Jingmin, Sun Xiaohua, Zou Lili, Ma Lina, Yan Hongsong. Effects of bioelectrical impedance test frequency on quantitative assessment of breast cancer associated lymphedema [J]. Journal of Capital Medical University, 2018, 39(5): 747-751.
[9]	Peng Nan, Liu Huimin, Wang Weixin, Liu Ming, Wang Zhiqun. Multi-parameters quantitative analysis of breast infiltrating ductal carcinoma as measured by diffusion weighted imaging and dynamic enhancement [J]. Journal of Capital Medical University, 2018, 39(2): 190-194.
[10]	Wang Lijuan, Yang Chun, Gu Muqing, Pierre Hardy, Ruan Xiangyan, Alfred O. Mueck. Relationship between progesterone-regulated microRNAs and breast cancer [J]. Journal of Capital Medical University, 2017, 38(4): 521-525.
[11]	Gu Muqing, Yang Chun, Wang Lijuan, Pierre Hardy, Jia Chanwei, Ruan Xiangyan. Current research studies of the relationship between miR-181a and breast cancers [J]. Journal of Capital Medical University, 2017, 38(4): 526-529.
[12]	Luo Chengyu. A paradigm shift from standard to precisely minimal invasion in breast cancer. [J]. Journal of Capital Medical University, 2016, 37(3): 331-335.
[13]	Wang Zihan, Teng Changsheng, Ge Zhicheng, Zhang Huiming, Yuan Zhu, Gao Yinguang, Zhang Zhongtao, Qu Xiang. Single port laparoscopic breast-conserving surgery in treatment of breast cancer [J]. Journal of Capital Medical University, 2016, 37(3): 336-340.
[14]	Cui Zhimiao, Luo Chengyu, Li Xin, Liu Baoyin, Ding Yi. Clinical application of nipple areola complex sparing modified mastoscopic mastectomy with one-stage reconstruction [J]. Journal of Capital Medical University, 2016, 37(3): 341-345.
[15]	Zhang Ying, Ruan Xiangyan, Mi Xin, Wang Gangyue, Alfred O. Mueck. Study of prognostic impact of progesterone receptor membrane component 1 (PGRMC1) in breast cancer patients [J]. Journal of Capital Medical University, 2015, 36(4): 548-552.